EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot aims to match existing treatment for rare autoimmune disease
Disease control OngoingThis study is testing whether a new long-acting injectable drug called depemokimab works as well as an existing drug called mepolizumab for adults with relapsing or hard-to-treat EGPA, a rare autoimmune disease. Both drugs are given as injections alongside standard steroid medica…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 02, 2026 02:11 UTC
-
New drug trial aims to tame rare 'Body-on-Fire' disease with fewer steroids
Disease control OngoingThis study compares a newer drug, mepolizumab, against standard steroid-based treatment for people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease. It aims to see if the new approach can better control disease flares and allow patients to use …
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC